Table 3.

Medical and surgical treatment before or co-administered with DBV. (*) Surgical procedures included: toilette of infected wound, bone debridement, drainage of abscesses. Acronym used—DBV: dalbavancin; MRSA: methicillin-resistant Staphylococcus aureus; IV: intravenous; po: oral; INR: international normalized ratio.

Surgery before DBV
N. of patients included	159 (35.3%)
Patients who underwent surgery before DBV* (n,%)	110 (69.2%)
Patients who did not undergo surgery before DBV (n,%)	49 (30.8%)
Antibiotics pre-DBV
N. of patients included	239 (53.1%)
None (n,%)	83 (34.7%)
Unspecified molecule (n,%)	64 (26.8%)
Anti-MRSA IV (n,%)	47 (19.7%)
Anti-MRSA AND anti-Gram-negative po (n,%)	16 (6.7%)
Anti-MRSA AND anti-Gram-negative IV (n,%)	14 (5.9%)
Anti-MRSA po (n,%)	8 (3.4%)
Anti-Gram-positive (n,%)	7 (2.9%)
Reason to switch to DBV
N. of patients included	96 (21.3%)
Failure of the previous antimicrobial regimen (n,%)	45 (46.9%)
Simplification (n,%)	19 (19.8%)
Adverse reaction (n,%)	14 (14.6%)
Other (n,%)	18 (18.8%)
Adverse reactions to DBV
N. of patients included	285 (63.3%)
No adverse reactions (n,%)	255 (89.5%)
Adverse reaction (n,%):	30 (10.5%)
➢ Unspecified (n,%)	13 (4.6%)
➢ Cutaneous (n,%)	7 (2.5%)
➢ Nausea (n,%)	6 (2.1%)
➢ Diarrhoea (n,%)	2 (0.7%)
➢ INR abnormalities (n,%)	1 (0.4%)
➢ Acute kidney injuries (n,%)	1 (0.4%)
Antibiotics co-administered
N. of patients included	238 (52.9%)
None (n,%)	182 (76.5%)
Unspecified molecule (n,%)	22 (9.2%)
Anti-MRSA AND anti-Gram-negative IV (n,%)	10 (4.2%)
Anti-MRSA AND anti-Gram-negative po (n,%)	13 (5.5%)
Anti-MRSA po (n,%)	11 (4.6%)